ClinicalTrials.gg
RecruitingNCT05947448Updated Apr 1, 2024

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

An observational study in Essential Hypertension, sponsored by Hasten Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Hasten Biopharmaceutical Co., Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,215
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Started
2024
with 7 others
Observational
9 of 76
2 open now
Primary completion
2025-06
later than 4 of 19 live
Registered
52nd of 76
by date

Among the 76 studies in Essential Hypertension with a site in China, this one is one of 8 that started in 2024, is one of 9 observational ones, reaches primary completion later than 4 of the 19 other live ones, and was the 52nd registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected

03

Conditions studied

  • Essential Hypertension

Keywords

  • essential hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

town hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old (one year old);
  2. Patients diagnosed with essential hypertension;
  3. Did not receive any antihypertensive drug treatment for at least 3 months before enrollment;
  4. Eligible to use 80 mg once-daily AZL-M at baseline or CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) or CCB (besylate Amlodipine tablets or nifedipine controlled-release tablets) + AZL-M 80 mg once-daily combination therapy; Volunteer to participate in this study, understand and sign the written .

Exclusion criteria

Exclusion Criteria:

  1. Used antihypertensive drugs for indications other than hypertension within 3 months before enrollment;
  2. Has a history of alcoholism, drug abuse or illegal drug use;
  3. Pregnant, breastfeeding women, and those who plan to become pregnant in the near future;
  4. is less than one year; Participating in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,215 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • AZL-M single drug group

    Azilsartan Medoxomil Potassium Tablet,80mg,tablet,QD,six months

    Drug: Azilsartan Medoxomil Potassium Tablet

  • CCB single drug group

    Nifedipine Controller-release Tablets,clinical maximum tolerated dose,tablet,QD,six months;or Levoamlodipine Maleate Table,clinical maximum tolerated dose,tablet,QD,six months; Doctor choose a medication that is more suitable for patient treatment.

    Drug: Nifedipine Sustained -release Tablets · Drug: Levoamlodipine Maleate Table

  • AZL-M + CCB drug group(Combined medication)

    Nifedipine Controller-release Tablets,clinical maximum tolerated dose,tablet,QD,six months;and Levoamlodipine Maleate Table,clinical maximum tolerated dose,tablet,QD,six months; When the patient's upper pressure exceeds 160 Millimetre of mercury, the doctor will choose combination medication .CCB drug will be chosen either Nifedipine Controller-release Tablets or Levoamlodipine Maleate Table.

    Drug: Azilsartan Medoxomil Potassium Tablet · Drug: Nifedipine Sustained -release Tablets · Drug: Levoamlodipine Maleate Table

Interventions

  • DrugAzilsartan Medoxomil Potassium Tablet

    Azilsartan Medoxomil Potassium Tablet,80mg,qd,lasts six month

  • DrugNifedipine Sustained -release Tablets

    Nifedipine Sustained -release Tablets,qd,The maximum clinical dose,lasts six months;

  • DrugLevoamlodipine Maleate Table

    Levoamlodipine Maleate Table,qd,The maximum clinical dose,lasts six months;

06

What researchers measure

Primary outcomes

  1. the patient's blood pressure reached the target rate

    Ø Compliance rate of systolic blood pressure (SBP) in the clinic: the proportion of subjects whose blood pressure dropped to sitting systolic blood pressure (sitSBP) \<140 mmHg or compared with the baseline value of sitSBP ≥ 20mmHg; Ø Compliance rate of diastolic blood pressure (DBP) in the clinic: the proportion of subjects whose blood pressure dropped to sitting diastolic blood pressure (sitDBP) \<90 mmHg or compared with the baseline value of sitDBP decreased by ≥10mmHg; Ø Achievement rate of both SBP and DBP in the clinic: the proportion of subjects who meet the SBP and DBP standards in the above clinics at the same time.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Junbo Ge
    Shanghai, Shanghai, China
    Recruiting
    • Junbo Ge · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2025, 17 months after the start.

Of 27 observational studies under Essential Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 52. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 17, 2023
StartActual
Jan 22, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05947448
Lead sponsor
Hasten Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Jan 22, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 1, 2024

Study contacts

Jun Bo Ge, academician
Contact
ge.junbo@zs-hospital.sh.cn
+86 13901977506

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion